| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 720.40 | 4.9% |
| Total Income | 758.10 | 7.0% |
| Expenditure | 611.80 | 4.7% |
| PBT | 146.30 | 17.9% |
| Net Profit | 109.70 | 19.6% |
| OPM | 11.85% | 0.30pp |
| NPM | 14.47% | 1.52pp |
| EPS | 4.59 | 19.5% |
Indegene Reports 4.9% QoQ Growth in Revenue, PAT Crosses INR 100 Crores for the Quarter
30 Jan 2025 · 30 Jan 2025, 11:26 pm
Summary
Indegene, a digital-first, life sciences commercialization company, announced its financial results for the quarter ended December 31, 2024. The company achieved a revenue of INR 7,204 million, a growth of 4.9% QoQ. The profit after tax (PAT) crossed INR 100 crores, reaching INR 1,097 million, a growth of 19.6% QoQ. Indegene also won Deloitte's #TechFast50 2024 Awards (India) in HealthTech for the second successive year.
Key Highlights
- 1
Achieved revenue of INR 7,204 million in Q3FY25, a growth of 4.9% QoQ
- 2
Achieved PAT of INR 1,097 million, a growth of 19.6% QoQ
- 3
Q3FY25 revenue growth driven by continued traction with large pharma customers and growth momentum with mid-size pharma customers
- 4
Steady increase in revenues from Top 5 customers, which have grown 3.1% sequentially
- 5
Improved EBITDA margin from 18.4% in Q2FY25 to 20.8% in Q3FY25
- 6
Earnings growth continues with PAT margin increasing to 15.2% for the quarter
- 7
Won Deloitte's #TechFast50 2024 Awards (India) in HealthTech for the second successive year
Management Comments
Manish Gupta
Chairman and CEO, Indegene Limited
We have consistently grown our revenue, maintaining stable and profitable growth, and our Q3FY25 numbers reflect this. We achieved revenue growth of 4.9% QoQ driven by continued traction with large pharma customers and growth momentum with mid-size pharma customers. Our largest customer is continuing to grow, and we are doing a run-rate of a tad below USD 50 million with this customer. We are seeing a steady increase in the revenues from our Top 5 customers, which have grown 3.1% sequentially in this period.
Suhas Prabhu
CFO, Indegene Limited
Q3FY25 was another successful quarter for Indegene. We improved our EBITDA margin from 18.4% in Q2FY25 to 20.8% in Q3FY25. This was achieved via ongoing productivity improvement through better capacity management and automation, which helped absorb the impact of the annual employee wage hike effective July, fully and beyond. Our earnings growth continues with PAT margin also increasing to 15.2% for the quarter, in line with our EBITDA performance. PAT has grown from INR 917 million in Q2FY25 to INR 1,097 million in Q3FY25, a growth of 19.6% sequentially.
Informational and educational content only. Not investment advice.